Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.

Cancer letters - 28 Aug 2017

Nakamura Yoshiaki, Hattori Naoko, Iida Naoko, Yamashita Satoshi, Mori Akiko, Kimura Kana, Yoshino Takayuki, Ushijima Toshikazu

Abstract excerpt

Bromodomain and extra-terminal (BET) inhibitors suppress super-enhancers and show cytotoxicity against multiple types of tumors. However, early clinical trials with BET inhibitors showed severe hematopoietic toxicities, highlighting the need for sensitive tumors and rational combination strategies to enhance their therapeutic potential. Here, we identified colon cancer-specific super-enhancers that were...

Topics

Join the communities discussing this publication.

Azepines
Caco-2 Cells
HCT116 Cells
HT29 Cells
Inhibitory Concentration 50

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28576751
DOI: 10.1016/j.canlet.2017.05.017

Genes

BRAF
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.PMID 28576751Read ↗

BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.Semantic proximity Read ↗

Reprogramming of Cellular Plasticity via ETS and MYC Core-regulatory Circuits During Response to MAPK Inhibition in BRAF-mutant Colorectal CancerSemantic proximity Read ↗

Reprogramming of Cellular Plasticity via ETS and MYC Core-Regulatory Circuits during Response to MAPK Inhibition in BRAF-Mutant Colorectal Cancer.Semantic proximity Read ↗

Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanomaSemantic proximity Read ↗

Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain InhibitionSemantic proximity Read ↗

Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.Semantic proximity Read ↗

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.Semantic proximity Read ↗

Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancerSemantic proximity Read ↗

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with VemurafenibSemantic proximity Read ↗

BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells.Semantic proximity Read ↗

KZ02 enhances the radiosensitivity of BRAF-mutated CRC in vitro and in vivo.Semantic proximity Read ↗

Mice deficient of <i>Myc</i> super-enhancer region reveal a differential control mechanism between normal and pathological growthSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.